Invizyne Technologies Inc. Common Stock (IZTC)
$
16.5
+1.00 (6.06%)
Key metrics
Financial statements
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Invizyne Technologies, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
News
defenseworld.net
a month ago
Protalix BioTherapeutics (NYSE: PLX - Get Free Report) and Invizyne Technologies (NASDAQ: IZTC - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership. Analyst Recommendations This is a breakdown of
See all news
